<p>阿尔凯默斯公司（NASDAQ:ALKS - 获取免费报告）在周三的午盘交易中，股价下跌了 6.7%，原因是其财报令人失望。该股票最低交易价格为 30.54 美元，最后交易价格为 31.1550 美元。午盘交易中大约交易了 670,308 股，较日均交易量 1,940,193 股下降了 65%。该股票此前收盘价为 33.39 美元。</p>
<p>该公司报告本季度每股收益（EPS）为 0.29 美元，低于市场共识预期的 0.43 美元，差距为 0.14 美元。阿尔凯默斯的股本回报率为 21.81%，净利润率为 22.27%。该公司本季度的收入为 3.8455 亿美元，而市场共识预期为 3.8044 亿美元。去年同期，该公司每股收益为 1.05 美元。本季度的收入较去年同期下降了 10.6%。阿尔凯默斯已将 2026 财年的指引设定为每股收益-0.798 至-0.680。</p>
<h2>阿尔凯默斯的热门头条</h2>
<p>以下是本周影响阿尔凯默斯的主要新闻：</p>
<ul>
<li>积极情绪：沃尔夫研究公司启动了对阿尔凯默斯的覆盖，给予 “跑赢大盘” 的评级和 45 美元的目标价——为当前水平提供了看涨的分析师催化剂和可观的上行空间。沃尔夫研究启动</li>
<li>积极情绪：董事会宣布有序的首席执行官接任：理查德·波普斯将于 2026 年 7 月 31 日退休，首席运营官布莱尔·杰克逊将于 2026 年 8 月 1 日成为首席执行官——减少了领导层的不确定性，表明了连续性。首席执行官接任新闻稿</li>
<li>中性情绪：阿尔凯默斯将在 TD Cowen 医疗会议上进行演讲——为投资者提供了可见性事件，但不是立即的收益驱动因素。会议演讲</li>
<li>中性情绪：媒体指出该公司最近在这些结果之前完成了对 Avadel 的收购——为收入/增长提供了战略背景，但影响取决于整合和利润率。Avadel 收购报道</li>
<li>中性情绪：报告的空头头寸数据噪声较大/归零，且对近期挤压没有信息价值（没有明确信号）。</li>
<li>消极情绪：第四季度每股收益未达标：阿尔凯默斯报告每股收益 0.29 美元，低于市场共识的 0.43 美元，收入为 3.846 亿美元（略高于预期），收入同比下降约 10.6%——表明利润率压力和盈利能力低于预期。收益新闻稿/幻灯片会议电话</li>
<li>消极情绪：2026 财年关键指引未达预期：阿尔凯默斯更新的每股收益指引为-0.798 至-0.680，而市场共识约为 1.63——这表明盈利能力展望显著疲软，解释了尽管收入指引接近市场，仍然出现负面市场反应。2026 财年指引新闻稿</li>
</ul>
<h2>分析师评级调整</h2>
<p>多家研究公司最近对 ALKS 进行了评估。韦斯评级在 12 月 29 日的报告中重新发布了对阿尔凯默斯的 “持有（c+）” 评级。华尔街 Zen 在 11 月 9 日的研究报告中将阿尔凯默斯的评级从 “强烈买入” 下调至 “买入”。Needham &amp; Company LLC 在 10 月 29 日的报告中将阿尔凯默斯的目标价从 43.00 美元提高至 44.00 美元，并给予该股票 “买入” 评级。美国银行在 2 月 20 日的报告中将阿尔凯默斯的目标价从 33.00 美元提高至 34.00 美元，并给予该公司 “中性” 评级。最后，沃尔夫研究在周一的研究报告中开始覆盖阿尔凯默斯，给予 “跑赢大盘” 评级和 45.00 美元的目标价。一位股票研究分析师给予该股票 “强烈买入” 评级，十二位给予 “买入” 评级，五位给予 “持有” 评级。根据 MarketBeat 的数据，阿尔凯默斯的共识评级为 “适度买入”，平均目标价为 44.00 美元。</p>
<p><strong>查看我们对 ALKS 的最新分析</strong></p>
<h2>内部交易活动</h2>
<p>在相关消息中，董事肖恩·库克于 2 月 2 日星期一出售了 61,200 股该股票，交易价格为每股 34.57 美元，总价值为 2,115,684.00 美元。出售后，该董事直接持有 103,744 股公司股票，价值为 3,586,430.08 美元。这代表其持股比例下降了 37.10%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此超链接获取。此外，执行副总裁克雷格·霍普金森于 2 月 2 日星期一出售了 9,000 股该公司的股票，交易价格为每股 33.93 美元，总交易额为 305,370.00 美元。完成出售后，该执行副总裁直接持有 57,740 股公司股票，价值约为 1,959,118.20 美元。该交易使其持股比例下降了 13.49%。有关此次出售的更多细节可在官方 SEC 披露中找到。过去一个季度，内部人士共出售了价值 5,028,378 美元的 148,148 股公司股票。目前，内部人士持有该股票的比例为 4.40%。</p>
<h2>阿尔凯默斯的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近买卖了该公司的股票。Baker BROS. Advisors LP 在第四季度将其在 Alkermes 的持股比例提高了 23.7%。Baker BROS. Advisors LP 目前拥有 10,012,267 股该公司的股票，价值 280,143,000 美元，此前在上个季度又购买了 1,920,916 股。State Street Corp 在第四季度将其在 Alkermes 的持股比例增加了 10.9%。State Street Corp 目前拥有 9,472,858 股该公司的股票，价值 265,051,000 美元，此前在此期间又购买了 932,507 股。Renaissance Technologies LLC 在第四季度将其在 Alkermes 的持股比例提高了 6.0%。Renaissance Technologies LLC 目前拥有 6,668,028 股该公司的股票，价值 186,571,000 美元，此前在此期间又购买了 375,500 股。JPMorgan Chase &amp; Co. 在第四季度将其在 Alkermes 的持股比例增加了 32.0%。JPMorgan Chase &amp; Co. 目前拥有 5,184,547 股该公司的股票，价值 145,064,000 美元，此前在上个季度又收购了 1,256,377 股。最后，Dimensional Fund Advisors LP 在第四季度将其在 Alkermes 的持股比例提高了 19.3%。Dimensional Fund Advisors LP 目前拥有 4,412,783 股该公司的股票，价值 123,467,000 美元，此前在此期间又收购了 714,787 股。对冲基金和其他机构投资者持有该公司 95.21% 的股票。</p>
<h2>Alkermes 股票下跌 5.4%</h2>
<p>该股票的市值为 52.2 亿美元，市盈率为 15.53，贝塔值为 0.49。该公司的 50 日移动平均价格为 31.38 美元，200 日移动平均价格为 30.17 美元。</p>
<h2>关于 Alkermes</h2>
<p>(获取免费报告)</p>
<p>Alkermes plc 是一家生物制药公司，专注于开发创新药物，以满足中枢神经系统 (CNS) 的未满足需求。该公司运用其专有的药物递送技术和治疗专业知识，推进对成瘾、精神分裂症、双相 I 型障碍和抑郁症的治疗。Alkermes 的产品组合包括商业产品和一系列旨在改善患者结果并支持长期疾病管理的研究疗法。</p>
<p>Alkermes 的商业特许经营包括多个已获批准的产品。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，胜过 Alkermes</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>这让我非常愤怒</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Alkermes 吗？</h2>
<p>在考虑 Alkermes 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Alkermes 并不在名单上。</p>
<p>虽然 Alkermes 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

基因改革 ETF - ARK

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>阿尔凯默斯（Alkermes plc，纳斯达克代码：ALKS）股价下跌 6.7%，至 31.1550 美元，原因是财报令人失望，报告每股收益（EPS）为 0.29 美元，低于预期的 0.43 美元。收入为 3.8455 亿美元，略高于预期，但同比下降 10.6%。公司对 2026 财年的每股收益指引设定在-0.798 至-0.680，显著低于市场共识。尽管财报表现不佳，Wolfe Research 仍给予其 “跑赢大盘” 的评级，并设定目标价为 45 美元。近期有内部人士出售股票，出售的股份数量较大。总体来看，该股票的市场共识评级为 “适度买入”，平均目标价为 44.00 美元</p>

<p>Alkermes plc (NASDAQ:ALKS - Get Free Report)'s share price was down 6.7% during mid-day trading on Wednesday following a dissappointing earnings announcement. The stock traded as low as $30.54 and last traded at $31.1550. Approximately 670,308 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 1,940,193 shares. The stock had previously closed at $33.39.</p>
<div class="lb-trans"><p>阿尔凯默斯公司（NASDAQ:ALKS - 获取免费报告）在周三的午盘交易中，股价下跌了 6.7%，原因是其财报令人失望。该股票最低交易价格为 30.54 美元，最后交易价格为 31.1550 美元。午盘交易中大约交易了 670,308 股，较日均交易量 1,940,193 股下降了 65%。该股票此前收盘价为 33.39 美元。</p>
</div><p>The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.14). Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The firm had revenue of $384.55 million during the quarter, compared to the consensus estimate of $380.44 million. During the same period last year, the firm posted $1.05 earnings per share. The company's revenue for the quarter was down 10.6% compared to the same quarter last year. Alkermes has set its FY 2026 guidance at -0.798--0.680 EPS.</p>
<div class="lb-trans"><p>该公司报告本季度每股收益（EPS）为 0.29 美元，低于市场共识预期的 0.43 美元，差距为 0.14 美元。阿尔凯默斯的股本回报率为 21.81%，净利润率为 22.27%。该公司本季度的收入为 3.8455 亿美元，而市场共识预期为 3.8044 亿美元。去年同期，该公司每股收益为 1.05 美元。本季度的收入较去年同期下降了 10.6%。阿尔凯默斯已将 2026 财年的指引设定为每股收益-0.798 至-0.680。</p>
</div><h2>Trending Headlines about Alkermes</h2>
<div class="lb-trans"><h2>阿尔凯默斯的热门头条</h2>
</div><p>Here are the key news stories impacting Alkermes this week:</p>
<div class="lb-trans"><p>以下是本周影响阿尔凯默斯的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Wolfe Research initiated coverage with an &#34;outperform&#34; rating and $45 price target — provides a bullish analyst catalyst and a sizable upside to current levels. Wolfe Research initiation</li>
<li>Positive Sentiment: Board announced an orderly CEO succession: Richard Pops will retire July 31, 2026, and COO Blair Jackson will become CEO Aug. 1, 2026 — reduces leadership uncertainty and signals continuity. CEO Succession Press Release</li>
<li>Neutral Sentiment: Alkermes to present at the TD Cowen Health Care Conference — visibility event for investors but not an immediate earnings driver. Conference presentation</li>
<li>Neutral Sentiment: Media noted the company recently closed the Avadel acquisition ahead of these results — strategic context for revenue/growth but impact depends on integration and margins. Avadel acquisition coverage</li>
<li>Neutral Sentiment: Reported short-interest data in the feed is noisy/zeroed out and not informative for near‑term squeezes (no clear signal).</li>
<li>Negative Sentiment: Q4 EPS missed: Alkermes reported $0.29 EPS vs. consensus $0.43, and revenue $384.6M (slightly above estimates) with revenue down ~10.6% y/y — suggests margin pressure and weaker profitability versus expectations. Earnings press release / slidesConference call</li>
<li>Negative Sentiment: Crucial FY‑2026 guidance missed expectations: Alkermes updated EPS guidance to -0.798 to -0.680 vs. consensus ~1.63 — a materially weaker profitability outlook that explains the negative market reaction despite revenue guidance near street. FY2026 guidance press release</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：沃尔夫研究公司启动了对阿尔凯默斯的覆盖，给予 “跑赢大盘” 的评级和 45 美元的目标价——为当前水平提供了看涨的分析师催化剂和可观的上行空间。沃尔夫研究启动</li>
<li>积极情绪：董事会宣布有序的首席执行官接任：理查德·波普斯将于 2026 年 7 月 31 日退休，首席运营官布莱尔·杰克逊将于 2026 年 8 月 1 日成为首席执行官——减少了领导层的不确定性，表明了连续性。首席执行官接任新闻稿</li>
<li>中性情绪：阿尔凯默斯将在 TD Cowen 医疗会议上进行演讲——为投资者提供了可见性事件，但不是立即的收益驱动因素。会议演讲</li>
<li>中性情绪：媒体指出该公司最近在这些结果之前完成了对 Avadel 的收购——为收入/增长提供了战略背景，但影响取决于整合和利润率。Avadel 收购报道</li>
<li>中性情绪：报告的空头头寸数据噪声较大/归零，且对近期挤压没有信息价值（没有明确信号）。</li>
<li>消极情绪：第四季度每股收益未达标：阿尔凯默斯报告每股收益 0.29 美元，低于市场共识的 0.43 美元，收入为 3.846 亿美元（略高于预期），收入同比下降约 10.6%——表明利润率压力和盈利能力低于预期。收益新闻稿/幻灯片会议电话</li>
<li>消极情绪：2026 财年关键指引未达预期：阿尔凯默斯更新的每股收益指引为-0.798 至-0.680，而市场共识约为 1.63——这表明盈利能力展望显著疲软，解释了尽管收入指引接近市场，仍然出现负面市场反应。2026 财年指引新闻稿</li>
</ul>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of research firms recently weighed in on ALKS. Weiss Ratings reissued a &#34;hold (c+)&#34; rating on shares of Alkermes in a report on Monday, December 29th. Wall Street Zen cut shares of Alkermes from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Sunday, November 9th. Needham &amp; Company LLC boosted their target price on shares of Alkermes from $43.00 to $44.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, October 29th. Bank of America increased their price target on shares of Alkermes from $33.00 to $34.00 and gave the company a &#34;neutral&#34; rating in a report on Friday, February 20th. Finally, Wolfe Research started coverage on Alkermes in a research report on Monday. They issued an &#34;outperform&#34; rating and a $45.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Alkermes has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $44.00.</p>
<div class="lb-trans"><p>多家研究公司最近对 ALKS 进行了评估。韦斯评级在 12 月 29 日的报告中重新发布了对阿尔凯默斯的 “持有（c+）” 评级。华尔街 Zen 在 11 月 9 日的研究报告中将阿尔凯默斯的评级从 “强烈买入” 下调至 “买入”。Needham &amp; Company LLC 在 10 月 29 日的报告中将阿尔凯默斯的目标价从 43.00 美元提高至 44.00 美元，并给予该股票 “买入” 评级。美国银行在 2 月 20 日的报告中将阿尔凯默斯的目标价从 33.00 美元提高至 34.00 美元，并给予该公司 “中性” 评级。最后，沃尔夫研究在周一的研究报告中开始覆盖阿尔凯默斯，给予 “跑赢大盘” 评级和 45.00 美元的目标价。一位股票研究分析师给予该股票 “强烈买入” 评级，十二位给予 “买入” 评级，五位给予 “持有” 评级。根据 MarketBeat 的数据，阿尔凯默斯的共识评级为 “适度买入”，平均目标价为 44.00 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on ALKS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ALKS 的最新分析</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In related news, Director Shane Cooke sold 61,200 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $34.57, for a total value of $2,115,684.00. Following the sale, the director directly owned 103,744 shares of the company's stock, valued at $3,586,430.08. This represents a 37.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Craig C. Hopkinson sold 9,000 shares of the firm's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $33.93, for a total transaction of $305,370.00. Following the completion of the sale, the executive vice president directly owned 57,740 shares of the company's stock, valued at approximately $1,959,118.20. The trade was a 13.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 148,148 shares of company stock worth $5,028,378 over the last quarter. 4.40% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事肖恩·库克于 2 月 2 日星期一出售了 61,200 股该股票，交易价格为每股 34.57 美元，总价值为 2,115,684.00 美元。出售后，该董事直接持有 103,744 股公司股票，价值为 3,586,430.08 美元。这代表其持股比例下降了 37.10%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此超链接获取。此外，执行副总裁克雷格·霍普金森于 2 月 2 日星期一出售了 9,000 股该公司的股票，交易价格为每股 33.93 美元，总交易额为 305,370.00 美元。完成出售后，该执行副总裁直接持有 57,740 股公司股票，价值约为 1,959,118.20 美元。该交易使其持股比例下降了 13.49%。有关此次出售的更多细节可在官方 SEC 披露中找到。过去一个季度，内部人士共出售了价值 5,028,378 美元的 148,148 股公司股票。目前，内部人士持有该股票的比例为 4.40%。</p>
</div><h2>Institutional Trading of Alkermes</h2>
<div class="lb-trans"><h2>阿尔凯默斯的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Baker BROS. Advisors LP lifted its position in shares of Alkermes by 23.7% during the fourth quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company's stock worth $280,143,000 after purchasing an additional 1,920,916 shares during the last quarter. State Street Corp increased its stake in Alkermes by 10.9% in the 4th quarter. State Street Corp now owns 9,472,858 shares of the company's stock worth $265,051,000 after buying an additional 932,507 shares during the period. Renaissance Technologies LLC boosted its position in Alkermes by 6.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,668,028 shares of the company's stock valued at $186,571,000 after buying an additional 375,500 shares during the period. JPMorgan Chase &amp; Co. grew its stake in Alkermes by 32.0% in the 4th quarter. JPMorgan Chase &amp; Co. now owns 5,184,547 shares of the company's stock worth $145,064,000 after acquiring an additional 1,256,377 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Alkermes by 19.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,412,783 shares of the company's stock worth $123,467,000 after acquiring an additional 714,787 shares during the period. Hedge funds and other institutional investors own 95.21% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近买卖了该公司的股票。Baker BROS. Advisors LP 在第四季度将其在 Alkermes 的持股比例提高了 23.7%。Baker BROS. Advisors LP 目前拥有 10,012,267 股该公司的股票，价值 280,143,000 美元，此前在上个季度又购买了 1,920,916 股。State Street Corp 在第四季度将其在 Alkermes 的持股比例增加了 10.9%。State Street Corp 目前拥有 9,472,858 股该公司的股票，价值 265,051,000 美元，此前在此期间又购买了 932,507 股。Renaissance Technologies LLC 在第四季度将其在 Alkermes 的持股比例提高了 6.0%。Renaissance Technologies LLC 目前拥有 6,668,028 股该公司的股票，价值 186,571,000 美元，此前在此期间又购买了 375,500 股。JPMorgan Chase &amp; Co. 在第四季度将其在 Alkermes 的持股比例增加了 32.0%。JPMorgan Chase &amp; Co. 目前拥有 5,184,547 股该公司的股票，价值 145,064,000 美元，此前在上个季度又收购了 1,256,377 股。最后，Dimensional Fund Advisors LP 在第四季度将其在 Alkermes 的持股比例提高了 19.3%。Dimensional Fund Advisors LP 目前拥有 4,412,783 股该公司的股票，价值 123,467,000 美元，此前在此期间又收购了 714,787 股。对冲基金和其他机构投资者持有该公司 95.21% 的股票。</p>
</div><h2>Alkermes Stock Down 5.4%</h2>
<div class="lb-trans"><h2>Alkermes 股票下跌 5.4%</h2>
</div><p>The stock has a market cap of $5.22 billion, a P/E ratio of 15.53 and a beta of 0.49. The company's 50 day moving average price is $31.38 and its two-hundred day moving average price is $30.17.</p>
<div class="lb-trans"><p>该股票的市值为 52.2 亿美元，市盈率为 15.53，贝塔值为 0.49。该公司的 50 日移动平均价格为 31.38 美元，200 日移动平均价格为 30.17 美元。</p>
</div><h2>About Alkermes</h2>
<div class="lb-trans"><h2>关于 Alkermes</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.</p>
<div class="lb-trans"><p>Alkermes plc 是一家生物制药公司，专注于开发创新药物，以满足中枢神经系统 (CNS) 的未满足需求。该公司运用其专有的药物递送技术和治疗专业知识，推进对成瘾、精神分裂症、双相 I 型障碍和抑郁症的治疗。Alkermes 的产品组合包括商业产品和一系列旨在改善患者结果并支持长期疾病管理的研究疗法。</p>
</div><p>Alkermes' commercial franchise features several approved products.</p>
<div class="lb-trans"><p>Alkermes 的商业特许经营包括多个已获批准的产品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Alkermes</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>This makes me furious</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Alkermes</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>这让我非常愤怒</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alkermes Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Alkermes 吗？</h2>
</div><p>Before you consider Alkermes, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Alkermes 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Alkermes 并不在名单上。</p>
</div><p>While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Alkermes 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

阿尔凯默斯（NASDAQ:ALKS）股价下跌 6.7%，因业绩不佳